Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 2/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25797756 | 0.89 | KMT2A (0.50) | MGLLFAAHCNR1KMT2ASMN1; SMN2 | |
| SCHEMBL18087016 | 0.85 | KMT2A (0.62) | KMT2ASMN1; SMN2RARBNPC1RAB9A | |
| SCHEMBL9652131 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9475902 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9476480 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9479205 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9477118 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9476333 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9479168 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA | |
| SCHEMBL9477155 | 0.84 | THRA (0.51) | MGLLKMT2ASMN1; SMN2RARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332008-A1 | PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230332008-A1 | PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332008-A1 | PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | COL1A1, MYB, HES1 | MGLL 3119/4885FAAH 3902/4885CNR1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.